The report gives the overview of Migraine disease indication in detail, highlights the Migraine epidemiology split into Episodic and Chronic Migraine prevalence in the key geographies and elaborates on the drugs prescribed and expected to be prescribed in acute and prophylactic treatment of Migraine.
The report elaborates on the Migraine disease indication detailing the definition, causes, subtypes of Migraine, profile of the patient, Symptoms of Migraine patients, and disease progression in Migraine patient. The report further highlights the multiple methods through which the patient can be diagnosed for Migraine.
The report mentions Migraine epidemiology and prevalence split into Episodic and Chronic Migraine in the key geographies across the globe like US, UK, Germany, Italy, France, Spain, Japan etc. The epidemiology for Migraine indication across key geographies has been forecasted till 2024 as well in the report.
The next part of the report highlights the importance of factors influencing the physician prescription decisions in Migraine like efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.
The report further details the drugs prescribed or expected to be prescribed in Migraine acute and prophylactic treatment by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the Migraine market.
Classification of Migraine based on symptoms and severity and based on frequency of attacks
Causes of Migraine
Profile of Migraine patient
Symptoms of Migraine patient
Disease progression and impact on QoL
Disease Epidemiology in key markets including Episodic and Chronic Migraine split
Factors influencing Physician prescription decision
DMTs for Migraine
- Eli Lilly
- Glaxo Smithkline
- Briston Mayers
- Allodynic Therapeutics
- Pharmalyte Solutions
- Ionis Pharmaceuticals
- Helsinn Group
- Otsuka Holdings
- NeurAxon Inc.
- Achelios Thera